BioSpace News Archive

Bexion Pharmaceuticals, Inc. announced today that the Company will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum.

Ultragenyx Pharmaceutical Inc. reported the grant of 80,366 restricted stock units of the company’s common stock and the grant of non-qualified stock options to purchase an aggregate of 140,469 shares of common stock of the company to Howard Horn, its newly appointed Chief Financial Officer and Executive Vice President, Corporate Strategy.

Ascentage Pharma announced that the Center for Drug Evaluation of China NMPA has approved a global pivotal registrational Phase III study designed to evaluate a key drug candidate in Ascentage Pharma’s pipeline, Bcl-2 inhibitor APG-2575, in combination with the Bruton’s tyrosine kinase inhibitor acalabrutinib.

Edesa Biotech, Inc. has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company’s first-in-class therapeutic candidate.

UCB, a global biopharmaceutical company, today announced the first analyses of pooled data from the two Phase 3 bimekizumab studies (BE HEARD I and BE HEARD II) in moderate-to-severe hidradenitis suppurativa (HS).

Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, reported today, initial results from the dose escalation parts of two Phase I-I/II studies for NMS-03305293 (NMS-293).

According to Vision Research Reports, the global medical device outsourcing market size was valued at USD 117.56 billion in 2022

Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd has signed a license deal with Korea-based CanariaBio Inc., acquiring the exclusive license to a new monoclonal antibody therapy for patients with ovarian cancer in Australia, New Zealand and in select Southeast Asian countries.

The Research Park at Florida Atlantic University® is pleased to announce that Instrumentum, an emerging leader in the surgical instrument sterilization field has located its headquarters in the Research Park at Florida Atlantic University®

Summit Medical Center is proud to announce that it has achieved the distinguished Gold Seal of Approval® for Advanced Total Hip and Knee Replacement Certification from The Joint Commission, the premier healthcare quality improvement and accrediting body in the nation.